CymaBay Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CymaBay Therapeutics, Inc.
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
Seladelpar may threaten an entrenched second-line therapy, Intercept’s Ocaliva, with better efficacy, based on benefits demonstrated in the pivotal RESPONSE trial.
India’s healthcare and life sciences segment saw deals worth over $3bn in Q2 2023 turbocharged by private equity activity in the hospitals space and smaller biopharma acquisitions. Watch the APIs and brands space for heightened M&A action, say experts.
Merck Life Science’s top executives in India tell Scrip how they are helping biologics companies in APAC on their mRNA therapy journey. In the wide-ranging discussion, use of AI, the startup environment for biotechs and the changing face of manufacturing in India also came up.
- Other Names / Subsidiaries
- Metabolex, Inc.
- Transplantation Technology, Inc.
- Transtech Corporation
- Transtech Medical, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.